Compared to usual care, the three-year programme averted 3,381 HIV infections.
From the perspective of the health system, averted medical costs were $1,169,887,000 and total investment was $599,096,000. The three-year programme resulted in cost-saving with a net benefit of $570,791,000, corresponding to a ROI of $1.95. ROI ranged from $1.46 to $2.01 for the one- to five-year alternative testing intervals. ROI remained above $1 in almost all scenarios and even with a prevalence of undiagnosed HIV infection as low as 0.12%.
From the perspective of CDC and partner investment, total investment was $126,384,000 and the consequent net benefit was $1,043,503,000, corresponding to a ROI of $9.26.
ROI ranged from $3.27 to $14.54 for the one- to five-year alternative testing intervals and remained above $1 in all scenarios with prevalence of undiagnosed HIV infection as low as 0.07%.